Andexanet alfa: administration quick reference guide (Guidelines)

Warning
Andexanet alfa must ONLY be administered on the advice of a Consultant Haematologist.

It is used to reverse the effects of rivaroxaban or apixaban in life-threatening or uncontrolled bleeding.

Patients should receive either a LOW DOSE or HIGH DOSE regimen depending on the time/dose of their last oral anticoagulant. Both are given as an initial loading dose (15 to 30 minutes) followed by a 2 hour infusion. See full administration guide for further details.
Low dose regimen = 400 mg loading dose followed by 480 mg over 2 hours.
High dose regimen = 800 mg loading dose followed by 960 mg over 2 hours.

Anticoagulant

Last Dose

Timing of last dose before andexanet alfa administration

Less than 8 hours or unknown 8 or more hours
Rivaroxaban ≤10 mg LOW dose LOW dose
>10 mg or unknown HIGH dose
Apixaban ≤5 mg LOW dose LOW dose
>5 mg or unknown HIGH dose

The volume, doses and rates required for each regimen is detailed below. Andexanet alfa comes as a 200 mg/20 mL vial (pack size of 4 vials). Dedicated syringe pumps with the loading and maintenance rates pre-programmed are available in each location andexanet is stocked, but as an additional safety measure these should be checked against the table below.

 

Low dose regimen

High dose regimen

Loading dose

Maintenance infusion

Loading dose

Maintenance infusion

Dose and millimetres required 400 mg in 40 mL 480 mg in 48 mL 800 mg in 80 mL 960 mg in 96 mL
Vials required 2 3 (discard remainder of vial 3) 4 5 (discard remainder of vial 5)
50mL syringes required One One Two = 40 mL per syringe Two = 48 mL per syringe
Rate of administration via syringe pump 160 mL/hr (bolus dose over 15 minutes) 24 mL/hr (over 2 hours) 160 mL/hour (over 30 minutes; each syringe will run for 15 minutes each) 48 mL/hr (over 2 hours; each syringe will run for 60 minutes each)


Once andexanet alfa has been administered please complete this form as soon as possible. 

Editorial Information

Last reviewed: 30/06/2021

Next review date: 30/06/2024

Author(s): Haematology .

Version: 1.1

Approved By: TAM subgroup of the ADTC

Reviewer name(s): Pharmacist.

Document Id: TAM479